BRPI0413574A - aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer - Google Patents

aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer

Info

Publication number
BRPI0413574A
BRPI0413574A BRPI0413574-1A BRPI0413574A BRPI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A
Authority
BR
Brazil
Prior art keywords
application
cancer therapy
cytotoxic factors
family polypeptides
methods
Prior art date
Application number
BRPI0413574-1A
Other languages
English (en)
Inventor
Amanda M Chakrabarty
Tapas K Das Gupta
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BRPI0413574A publication Critical patent/BRPI0413574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"APLICAçãO DE POLIPEPTìDEOS DA FAMìLIA CUPREDOXINA NA TERAPIA DO CáNCER". São revelados fatores citotóxicos tendo aplicação na modulação da morte celular, e sua aplicação em métodos para tratar condições relacionadas com necroses ou apoptose. A invenção também refere-se a métodos para identificar agentes ativos úteis para tratar condições relacionadas com morte celular ou crescimento descontrolado. Os inventores presentes descobriram que diferentes microorganismos produzem diferentes fatores citotóxicos tendo atividade anticancerígena. Os fatores citotóxicos essencialmente puros podem ser usados em um método para tratar uma doença infecciosa ou um câncer.
BRPI0413574-1A 2003-08-15 2004-08-10 aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer BRPI0413574A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
BRPI0413574A true BRPI0413574A (pt) 2006-10-17

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413574-1A BRPI0413574A (pt) 2003-08-15 2004-08-10 aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer

Country Status (19)

Country Link
US (4) US7491394B2 (pt)
EP (2) EP2263682A1 (pt)
JP (1) JP2007502818A (pt)
KR (1) KR20060098358A (pt)
AP (1) AP2006003537A0 (pt)
AT (1) ATE470672T1 (pt)
AU (1) AU2004266632A1 (pt)
BR (1) BRPI0413574A (pt)
CA (1) CA2535581A1 (pt)
DE (1) DE602004027637D1 (pt)
EA (1) EA009897B1 (pt)
EC (1) ECSP066422A (pt)
GE (1) GEP20105022B (pt)
IL (1) IL173576A0 (pt)
NO (1) NO20061168L (pt)
NZ (1) NZ545355A (pt)
OA (1) OA13308A (pt)
TN (1) TNSN06059A1 (pt)
WO (1) WO2005018662A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
AP2007003959A0 (en) 2004-10-07 2007-04-30 Ananda Chakrabarty Cupredoxin derived transport agents and methods ofuse thereof
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
CA2608398A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
MX2007014597A (es) * 2005-05-20 2008-01-21 Univ Illinois Composiciones y metodos para el tratamiento de malaria con cupredoxina y citocromo.
CA2608512A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
KR20080034905A (ko) * 2005-07-19 2008-04-22 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 혈관신생을 제어하는 조성물과 방법
MX2008000994A (es) 2005-07-19 2008-03-19 Univ Illinois Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos.
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
EP2061487A4 (en) 2006-09-11 2009-12-02 Univ Illinois MODIFIED CUPREDOXIN-DERIVED PEPTIDES AND METHOD FOR THEIR USE
SG174784A1 (en) * 2006-09-14 2011-10-28 Univ Illinois Compositions and methods to prevent cancer with cupredoxins
KR20090095626A (ko) 2006-12-04 2009-09-09 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 ＣｐＧ 리치 ＤＮＡ를 이용한 조성물 및 암 치료 방법
WO2008086523A2 (en) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
AU2008212788A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
CA2734363C (en) * 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
WO2016176573A1 (en) * 2015-04-30 2016-11-03 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
EP0737750B1 (en) 1989-03-21 2003-05-14 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
CA2102918C (en) 1992-03-11 2007-05-08 Joel R. Haynes Genetic vaccine for immunodeficiency viruses
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
CA2664797A1 (en) 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
AP2007003959A0 (en) 2004-10-07 2007-04-30 Ananda Chakrabarty Cupredoxin derived transport agents and methods ofuse thereof
CA2608398A1 (en) 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
MX2007014597A (es) 2005-05-20 2008-01-21 Univ Illinois Composiciones y metodos para el tratamiento de malaria con cupredoxina y citocromo.
MX2008000994A (es) 2005-07-19 2008-03-19 Univ Illinois Agentes de transporte para cruzar la barrera hematoencefalica y hacia el interior de las celulas de cancer cerebral, y metodos para el uso de los mismos.

Also Published As

Publication number Publication date
US20140179617A1 (en) 2014-06-26
EP1653990A1 (en) 2006-05-10
US7491394B2 (en) 2009-02-17
NZ545355A (en) 2009-10-30
EP1653990B1 (en) 2010-06-09
US20060040269A1 (en) 2006-02-23
AP2006003537A0 (en) 2006-04-30
ECSP066422A (es) 2006-11-24
US7888468B2 (en) 2011-02-15
AU2004266632A1 (en) 2005-03-03
NO20061168L (no) 2006-05-15
US20080182782A1 (en) 2008-07-31
US20060292136A1 (en) 2006-12-28
EA200600424A1 (ru) 2006-08-25
TNSN06059A1 (en) 2007-10-03
KR20060098358A (ko) 2006-09-18
OA13308A (en) 2007-04-13
JP2007502818A (ja) 2007-02-15
CA2535581A1 (en) 2005-03-03
ATE470672T1 (de) 2010-06-15
EA009897B1 (ru) 2008-04-28
EP2263682A1 (en) 2010-12-22
GEP20105022B (en) 2010-06-25
IL173576A0 (en) 2006-07-05
DE602004027637D1 (de) 2010-07-22
WO2005018662A1 (en) 2005-03-03
US10421801B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
BR0110420A (pt) Agonistas muscarìnicos
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
GEP20022804B (en) Erythropoietin Derivatives
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
NO20025450D0 (no) Ny farmasöytisk sammensetning
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
ATE461707T1 (de) Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
WO2024026308A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
ATE406158T1 (de) Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.